Synthesis of deuterium‐labelled trantinterol

Abstract

Trantinterol, a selective b 2 -adrenoceptor agonist, is currently in Phase II clinical trials for the treatment of asthma and bronchitis. The synthesis of deuterium-labelled trantinterol is described. The labelled trantinterol is used as an internal standard for the analysis and metabolic studies.